Scholarly Articles (2015-2020)

Defects in fatty acid amide hydrolase 2 in a male with neurologic and -sychiatric symptoms (Canada/ USA) (full – 2015)
Increased Cortical Inhibition in Autism-Linked Neuroligin-3R451C Mice Is Due in Part to Loss of Endocannabinoid Signaling. (USA) (full – 2015)
Endocannabinoid signaling mediates oxytocin-driven social reward. (USA/ Spain/ Italy) (full – 2015)
Medical marijuana: review of the science and implications for developmental-behavioral pediatric practice. (USA) (full – 2015)
Endocannabinoid Signaling in Autism. (Italy/ UK) (full – 2015)
β-Neurexins Control Neural Circuits by Regulating Synaptic Endocannabinoid Signaling (USA/ Japan) (full – 2015)
The basolateral amygdala γ-aminobutyric acidergic system in health and disease (USA) (full – 2015)
Endocannabinoid signaling mediates oxytocin-driven social reward. (USA/ Spain/ Italy)
(full – 2015)
Endocannabinoids and Neurodegenerative Disorders: Parkinson’s Disease, Huntington’s
Chorea, Alzheimer’s Disease, and Others. (Spain) (download – 2015)
Endocannabinoids and Mental Disorders. (Italy) (partial preview – 2015)
p21-activated kinase 1 restricts tonic endocannabinoid signaling in the hippocampus (Canada / China) (full – 2016)
Endocannabinoid signaling in social functioning: an RDoC perspective. (USA) (full – 2016)
Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid. (Italy) (full – 2016)
Acetaminophen Use for Fever in Children Associated with Autism Spectrum Disorder (USA) (full – 2016)
Deficient adolescent social behavior following early-life inflammation is ameliorated by augmentation of anandamide signaling. (Canada/ USA) (full – 2016)
Functions of synapse adhesion molecules neurexin/neurexins and neurodevelopmental disorders. (Japan) (link to PDF – 2016)
Involvement of TRPV1 in the Olfactory Bulb in Rimonabant-Induced Olfactory Discrimination Deficit. (China) (download – 2016)
Pharmacological inhibition of fatty acid amide hydrolase attenuates social behavioural deficits in male rats prenatally exposed to valproic acid. (Ireland) (abst – 2016)
Cannabinoids in Pediatrics. (USA) (full – 2017)
Endocannabinod Signal Dysregulation in Autism Spectrum Disorders: A Correlation Link between Inflammatory State and Neuro-Immune Alterations. (Italy/ USA) (full – 2017)
Role of Endocannabinoids on Neuroinflammation in Autism Spectrum Disorder Prevention. (Saudi Arabia) (full – 2017)
The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models. (Italy) (full – 2017)
Rare genetic variants in the endocannabinoid system genes CNR1 and DAGLA are associated with neurological phenotypes in humans. (USA) (full – 2017)
The Search for an Effective Therapy to Treat Fragile X Syndrome: Dream or Reality? (France) (full – 2017)
Synaptic functions of endocannabinoid signaling in health and disease (USA/ France/ Italy) (full – 2017)
Treating a novel plasticity defect rescues episodic memory in Fragile X model mice (USA) (full – 2017)
Chronic Inflammatory Pain Impairs mGluR5-Mediated Depolarization-Induced Suppression of Excitation in the Anterior Cingulate Cortex. (China) (full -2017)
The Neurobiological Bases of Autism Spectrum Disorders The R451C-Neuroligin 3 mutation hampers the expression of long-term synaptic depression in the dorsal  striatum (Italy) (abst – 2017)
Plasma anandamide concentrations are lower in children with autism spectrum disorder (USA) (full – 2018)
An Inflammation-Centric View of Neurological Disease: Beyond the Neuron. (Italy) (full – 2018)
Altered Amygdala Excitation and CB1 Receptor Modulation of Aggressive Behavior in the Neuroligin-3R451C Mouse Model of Autism. (Australia/ New Zealand) (full – 2018)
Lipidome alterations in human prefrontal cortex during development, aging, and cognitive disorders. (China/ Russia/ USA/ Germany) (full – 2018)
Sex specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signaling. (Italy) (full – 2018)
Role of Striatal Direct Pathway 2-Arachidonoylglycerol Signaling in Sociability and Repetitive Behavior. (USA) (full – 2018)
Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility Study. (Israel) (link to PDF – 2018)
Relationships between substance abuse/dependence and psychiatric disorders based on polygenic scores. (Spain) (link to PDF – 2018)
Cannabidiol as a suggested candidate for treatment of autism spectrum disorder (Israel) (click “drcannabiscombr” for download – 2018)
Cannabinoids: just like any other medication? (UK) (article – 2018)
Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial. (Iran) (abst – 2018)
Cannabinoids in the Treatment of Autism Spectrum Disorder: Demanding Data Before Using Fad Therapies. (USA) (abst – 2018)
Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy. (Israel) (full – 2019)
Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. (UK/ USA) (full – 2019)
The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). (UK) (full – 2019)
Metabolomics and Communication Skills Development in Children; Evidence from the Ages and Stages Questionnaire. (USA) (full – 2019)
Lower circulating endocannabinoid levels in children with autism spectrum disorder (Israel) (full – 2019)
Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats. (Italy/ UK) (full -2019)
Comparative psychopharmacology of autism and psychotic-affective disorders suggests new targets for treatment. (Canada) (full – 2019)
Molecular Pathology and Pharmacological Treatment of Autism Spectrum Disorder-Like Phenotypes Using Rodent Models. (Taiwan) (full – 2019)
The Endocannabinoid System as a Window Into Microglial Biology and Its Relationship to Autism (USA) (full – 2019)
Current state of evidence of cannabis utilization for treatment of autism spectrum disorders (USA) (full – 2019)
Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use (Brazil) (full – 2019)
Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy. (UK/ USA) (full – 2019)
Ethical Implications for Providers Regarding Cannabis Use in Children With Autism Spectrum Disorders. (USA) (click “aappublicationsorg” for full – 2019)
The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review. (USA) (link to PDF – 2019)
An endocannabinoid-regulated basolateral amygdala-nucleus accumbens circuit modulates sociability. (USA) (link to PDF- 2019)
Targeting the inhibition of fatty acid amide hydrolase ameliorate the endocannabinoid mediated synaptic dysfunction in a valproic acid-induced rat model of Autism (Taiwan -abst–2019)
CB1 receptor antagonism in capuchin monkeys alters social interaction and aversive memory extinction. (Brazil/ Japan) (abst – 2019)
Role of the endocannabinoid system in neurological disorders. (China) (abst – 2019)
Synthetic cannabinoids and their impact on neurodevelopmental processes. (Portugal) (abst – 2019)
Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment (Italy/ Sweden) (abst – 2019)
Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. (Israel) (abst – 2019)
Phytocannabinoids in Neurological Diseases: Could They Restore a Physiological GABAergic Transmission? (Italy/ Netherlands) (full – 2020)
Medical Cannabis in Children. (Israel) (link to download – 2020)
Medicinal Use of Cannabis in Children and Pregnant Women. (Israel) (click “researchgate” for download – 2020)

United States Patent 6630507

Cannabinoids as antioxidants and neuroprotectants